Long-lasting blocking of interoceptive effects of cocaine by a highly efficient cocaine hydrolase in rats.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 Jan 2024
09 Jan 2024
Historique:
received:
12
09
2023
accepted:
22
12
2023
medline:
10
1
2024
pubmed:
10
1
2024
entrez:
9
1
2024
Statut:
epublish
Résumé
Cocaine dependence is a serious world-wide public health problem without an FDA-approved pharmacotherapy. We recently designed and discovered a highly efficient long-acting cocaine hydrolase CocH5-Fc(M6). The present study examined the effectiveness and duration of CocH5-Fc(M6) in blocking interoceptive effects of cocaine by performing cocaine discrimination tests in rats, demonstrating that the duration of CocH5-Fc(M6) in blocking cocaine discrimination was dependent on cocaine dose and CocH5-Fc(M6) plasma concentration. Particularly, a dose of 3 mg/kg CocH5-Fc(M6) effectively attenuated discriminative stimulus effects of 10 mg/kg cocaine, cumulative doses of 10 and 32 mg/kg cocaine, and cumulative doses of 10, 32 and 56 mg/kg cocaine by ≥ 20% for 41, 19, and 10 days, and completely blocked the discriminative stimulus effects for 30, 13, and 5 days with corresponding threshold plasma CocH5-Fc(M6) concentrations of 15.9, 72.2, and 221 nM, respectively, under which blood cocaine concentration was negligible. Additionally, based on the data obtained, cocaine discrimination model is more sensitive than the locomotor activity to reveal cocaine effects and that CocH5-Fc(M6) itself has no long-term toxicity regarding behavioral activities such as lever pressing and food consumption in rats, further demonstrating that CocH5-Fc(M6) has the desired properties as a promising therapeutic candidate for prevenance of cocaine dependence.
Identifiants
pubmed: 38195724
doi: 10.1038/s41598-023-50678-0
pii: 10.1038/s41598-023-50678-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
927Subventions
Organisme : NIH HHS
ID : U01 DA051079
Pays : United States
Organisme : NIH HHS
ID : UH2/UH3 DA041115
Pays : United States
Organisme : NIH HHS
ID : R01 DA056646
Pays : United States
Organisme : NIH HHS
ID : UG3 NS134920
Pays : United States
Organisme : NIH HHS
ID : U18 DA052319
Pays : United States
Organisme : NIH HHS
ID : R01 DA035552
Pays : United States
Organisme : NIH HHS
ID : R01 DA032910
Pays : United States
Organisme : NIH HHS
ID : R01 DA013930
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
World Drug Report from the United Nations Office on Drugs and Crime; 2021.
Vallecillo, G., Perelló, R., Güerri, R., Fonseca, F. & Torrens, M. Clinical impact of COVID-19 on people with substance use disorders. J. Public Health 43(1), 9–12. https://doi.org/10.1093/pubmed/fdaa181 (2020).
doi: 10.1093/pubmed/fdaa181
Wei, Y. & Shah, R. Substance use disorder in the COVID-19 pandemic: A systematic review of vulnerabilities and complications. Pharmaceuticals 13(7), 155 (2020).
doi: 10.3390/ph13070155
pubmed: 32708495
pmcid: 7407364
Avena, N. M., Simkus, J., Lewandowski, A., Gold, M. S. & Potenza, M. N. Substance use disorders and behavioral addictions during the COVID-19 pandemic and COVID-19-related restrictions. Front. Psychiatry 12, 653674. https://doi.org/10.3389/fpsyt.2021.653674 (2021).
doi: 10.3389/fpsyt.2021.653674
pubmed: 33935838
pmcid: 8085389
NIDA. Overdose Death Rates in 2020, https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates .
Jalal, H. et al. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science 361(6408), eaau1184. https://doi.org/10.1126/science.aau1184 (2018).
doi: 10.1126/science.aau1184
pubmed: 30237320
pmcid: 8025225
Hedegaard, H., Miniño, A. M. & Warner, M. Drug overdose deaths in the United States, 1999–2018. NCHS Data Brief 356, 1–8 (2020).
Brandt, L., Chao, T., Comer, S. D. & Levin, F. R. Pharmacotherapeutic strategies for treating cocaine use disorder—What do we have to offer?. Addiction 116(4), 694–710 (2021).
doi: 10.1111/add.15242
pubmed: 32888245
Abuse, S. Mental Health Services Administration (SAHMSA). Mental and Substance Use Disorders. 2018.
Bentzley, B. S. et al. Comparison of treatments for cocaine use disorder among adults: A systematic review and meta-analysis. JAMA Netw. Open 4(5), e218049–e218049. https://doi.org/10.1001/jamanetworkopen.2021.8049(acccessed1/31/2023) (2021).
doi: 10.1001/jamanetworkopen.2021.8049(acccessed1/31/2023)
pubmed: 33961037
pmcid: 8105751
Kampman, K. M. The treatment of cocaine use disorder. Sci. Adv. 5(10), eaax1532. https://doi.org/10.1126/sciadv.aax1532 (2019).
doi: 10.1126/sciadv.aax1532
pubmed: 31663022
pmcid: 6795516
Penberthy, J. K., Ait-Daoud, N., Vaughan, M. & Fanning, T. Review of treatment for cocaine dependence. Curr. Drug Abuse Rev. 3(1), 49–62. https://doi.org/10.2174/1874473711003010049 (2010).
doi: 10.2174/1874473711003010049
pubmed: 20088819
Kosten, T. R. et al. Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend. 140, 42–47. https://doi.org/10.1016/j.drugalcdep.2014.04.003 (2014).
doi: 10.1016/j.drugalcdep.2014.04.003
pubmed: 24793366
pmcid: 4073297
Martell, B. A. et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: A randomized, double-blind, placebo-controlled efficacy trial. Arch. Gen. Psychiatry 66(10), 1116–1123. https://doi.org/10.1001/archgenpsychiatry.2009.128 (2009).
doi: 10.1001/archgenpsychiatry.2009.128
pubmed: 19805702
pmcid: 2878137
Bloom, B. T. & Bushell, M. J. Vaccines against drug abuse-are we there yet?. Vaccines https://doi.org/10.3390/vaccines10060860 (2022).
doi: 10.3390/vaccines10060860
pubmed: 35746468
pmcid: 9230984
Gao, D. et al. Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation. Angew. Chem. Int. Ed. 45(4), 653–657 (2006).
doi: 10.1002/anie.200503025
Gao, D. & Zhan, C.-G. Modeling evolution of hydrogen bonding and stabilization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase. Proteins Struct. Funct Bioinform. 62(1), 99–110. https://doi.org/10.1002/prot.20713 (2006).
doi: 10.1002/prot.20713
Pan, Y., Gao, D., Yang, W., Cho, H. & Zhan, C.-G. Free energy perturbation (FEP) simulation on the transition states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants. J. Am. Chem. Soc. 129(44), 13537–13543. https://doi.org/10.1021/ja073724k (2007).
doi: 10.1021/ja073724k
pubmed: 17927177
pmcid: 2792569
Pan, Y., Muzyka, J. & Zhan, C.-G. Model of human butyrylcholinesterase (BChE) tetramer by homology modeling and dynamics simulation. J. Phys. Chem. B 113, 6543–6552 (2009).
doi: 10.1021/jp8114995
pubmed: 19402731
pmcid: 2755204
Zhan, C.-G. Novel pharmacological approaches to treatment of drug overdose and addiction. Expert Rev. Clin. Pharmacol. 2, 1–4 (2009).
doi: 10.1586/17512433.2.1.1
pubmed: 21072135
pmcid: 2975360
Yang, W. et al. Free-energy perturbation simulation on transition states and redesign of butyrylcholinesterase. Biophys. J. 96(5), 1931–1938 (2009).
doi: 10.1016/j.bpj.2008.11.051
pubmed: 19254552
pmcid: 2717303
Zheng, F. & Zhan, C.-G. Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anti-cocaine medications. Future Med. Chem. 1, 515–528 (2009).
doi: 10.4155/fmc.09.20
pubmed: 20161378
Zheng, F. et al. Design of high-activity mutants of human butyrylcholinesterase against (−)-cocaine: Structural and energetic factors affecting the catalytic efficiency. Biochemistry 49, 9113–9119 (2010).
doi: 10.1021/bi1011628
pubmed: 20886866
Zheng, F. & Zhan, C.-G. Enzyme therapy approaches for treatment of drug overdose and addiction. Future Med. Chem. 3, 9–13 (2011).
doi: 10.4155/fmc.10.275
pubmed: 21428822
Xue, L. et al. Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol. Pharmacol. 79, 290–297 (2011).
doi: 10.1124/mol.110.068494
pubmed: 20971807
pmcid: 3033707
Hou, S. et al. Substrate selectivity of high-activity mutants of human butyrylcholinesterase. Org. Biomol. Chem. 11, 7477–7485 (2013).
doi: 10.1039/c3ob41713a
pubmed: 24077614
pmcid: 3836059
Zheng, F. & Zhan, C.-G. Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse. PLoS Comput. Biol. 8, e1002610 (2012).
doi: 10.1371/journal.pcbi.1002610
pubmed: 22844238
pmcid: 3406004
Zheng, F. & Zhan, C.-G. Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose?. Future Med. Chem. 4, 125–128 (2012).
doi: 10.4155/fmc.11.171
pubmed: 22300091
Xue, L. et al. Catalytic activities of a cocaine hydrolase engineered from human butyrylcholinesterase against (+)- and (−)-cocaine. Chem. Biol. Interact. 203, 57–62 (2013).
doi: 10.1016/j.cbi.2012.08.003
pubmed: 22917637
Xue, L. et al. Preparation and in vivo characterization of a cocaine hydrolase engineered from human butyrylcholinesterase for metabolizing cocaine. Biochem. J. 453, 447–454 (2013).
doi: 10.1042/BJ20130549
pubmed: 23849058
Zhan, M., Hou, S., Zhan, C.-G. & Zheng, F. Kinetic characterization of high-activity mutants of human butyrylcholinesterase for the cocaine metabolite norcocaine. Biochem. J. 457, 197–206 (2014).
doi: 10.1042/BJ20131100
pubmed: 24125115
Hou, S., Zhan, M., Zheng, X., Zhan, C.-G. & Zheng, F. Kinetic characterization of human butyrylcholinesterase mutants for hydrolysis of cocaethylene. Biochem. J. 460, 447–457 (2014).
doi: 10.1042/BJ20140360
pubmed: 24870023
Chen, X. et al. Kinetic characterization of a cocaine hydrolase engineered from mouse butyrylcholinesterase. Biochem. J. 466, 243–251. https://doi.org/10.1042/BJ20141266 (2015).
doi: 10.1042/BJ20141266
pubmed: 25486543
Chen, X., Zheng, X., Zhou, Z., Zhan, C.-G. & Zheng, F. Effects of a cocaine hydrolase engineered from human butyrylcholinesterase on metabolic profile of cocaine in rats. Chem. Biol. Interact. 259, 104–109 (2016).
doi: 10.1016/j.cbi.2016.05.003
pubmed: 27154495
pmcid: 5094907
Chen, X. et al. Metabolic enzymes of cocaine metabolite benzoylecgonine. ACS Chem. Biol. 11, 2186–2194 (2016).
doi: 10.1021/acschembio.6b00277
pubmed: 27224254
pmcid: 5626564
Zheng, F. & Zhan, C.-G. Cocaine hydrolases designed from butyrylcholinesterase. In Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes (ed. Montoya, I. D.) 187–225 (Springer, 2016).
doi: 10.1007/978-3-319-23150-1_12
Zheng, F. & Zhan, C.-G. Actions of butyrylcholinesterase against cocaine. In The Neuroscience of Cocaine: Mechanism and Treatment Vol. 2017 (ed. Preedy, V. R.) 663–672 (Academic Press, 2017).
doi: 10.1016/B978-0-12-803750-8.00067-1
Cai, Y. et al. Reengineering of albumin-fused cocaine hydrolase CocH1 (TV-1380) to prolong its biological half-life. AAPS J. 22, 5. https://doi.org/10.1208/s12248-12019-10377-z (2019).
doi: 10.1208/s12248-12019-10377-z
pubmed: 31754920
Chen, X. et al. Development of a long-acting Fc-fused cocaine hydrolase with improved yield of protein expression. Chem. Biol. Interact. 306, 89–95 (2019).
doi: 10.1016/j.cbi.2019.04.012
pubmed: 30986387
pmcid: 6555559
Zheng, X. et al. Catalytic activities of cocaine hydrolases against the most toxic cocaine metabolite norcocaethylene. Org. Biomol. Chem. 18, 1968–1977 (2020).
doi: 10.1039/C9OB02762A
pubmed: 32101217
pmcid: 7362898
Zhan, M. et al. Kinetic characterization of an efficient cocaine hydrolase against toxic metabolites of cocaine. Org. Biomol. Chem. 21(17), 3650–3659. https://doi.org/10.1158/1535-7163.mct-07-0484 (2023).
doi: 10.1158/1535-7163.mct-07-0484
pubmed: 37067022
Zheng, X. et al. Effectiveness of a cocaine hydrolase for cocaine toxicity treatment in male and female rats. AAPS J. 20, 3. https://doi.org/10.1208/s12248-12017-10167-12244 (2018).
doi: 10.1208/s12248-12017-10167-12244
Chen, X. et al. Development of Fc-fused cocaine hydrolase for cocaine addiction: Catalytic and pharmacokinetic properties. AAPS J. 20, 53. https://doi.org/10.1208/s12248-12018-10214-12249 (2018).
doi: 10.1208/s12248-12018-10214-12249
pubmed: 29556863
Sun, H., Pang, Y. P., Lockridge, O. & Brimijoin, S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol. Pharmacol. 62(2), 220–224. https://doi.org/10.1124/mol.62.2.220 (2002).
doi: 10.1124/mol.62.2.220
pubmed: 12130672
Brimijoin, S. et al. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33(11), 2715–2725 (2008).
doi: 10.1038/sj.npp.1301666
pubmed: 18199998
Zheng, F. et al. Most efficient cocaine hydrolase designed by virtual screening of transition states. J. Am. Chem. Soc. 130(36), 12148–12155. https://doi.org/10.1021/ja803646tFromNLM (2008).
doi: 10.1021/ja803646tFromNLM
pubmed: 18710224
pmcid: 2646118
Zheng, F. et al. A highly efficient cocaine-detoxifying enzyme obtained by computational design. Nat. Commun. 5, 3457. https://doi.org/10.1038/ncomms4457 (2014).
doi: 10.1038/ncomms4457
pubmed: 24643289
Pan, Y. et al. Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc. Natl. Acad. Sci. 102(46), 16656–16661. https://doi.org/10.1073/pnas.0507332102 (2005).
doi: 10.1073/pnas.0507332102
pubmed: 16275916
pmcid: 1283827
Cohen-Barak, O. et al. Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects. J. Clin. Pharmacol. 55(5), 573–583. https://doi.org/10.1002/jcph.450 (2015).
doi: 10.1002/jcph.450
pubmed: 25524052
pmcid: 4402032
Shram, M. J. et al. Assessment of pharmacokinetic and pharmacodynamic interactions between albumin-fused mutated butyrylcholinesterase and intravenously administered cocaine in recreational cocaine users. J. Clin. Psychopharmacol. 35(4), 396–405. https://doi.org/10.1097/jcp.0000000000000347 (2015).
doi: 10.1097/jcp.0000000000000347
pubmed: 26082975
Gilgun-Sherki, Y. et al. Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence. Drug Alcohol Depend. 166, 13–20. https://doi.org/10.1016/j.drugalcdep.2016.05.019 (2016).
doi: 10.1016/j.drugalcdep.2016.05.019
pubmed: 27394932
Shemesh-Darvish, L., Shinar, D., Hallak, H., Gross, A. & Rosenstock, M. TV-1380 attenuates cocaine-induced changes in cardiodynamic parameters in monkeys and reduces the formation of cocaethylene. Drug Alcohol Depend. 188, 295–303. https://doi.org/10.1016/j.drugalcdep.2018.01.033 (2018).
doi: 10.1016/j.drugalcdep.2018.01.033
pubmed: 29807217
Gao, Y. et al. An albumin–butyrylcholinesterase for cocaine toxicity and addiction: Catalytic and pharmacokinetic properties. Chem. Biol. Interact. 175(1), 83–87. https://doi.org/10.1016/j.cbi.2008.04.024 (2008).
doi: 10.1016/j.cbi.2008.04.024
pubmed: 18514640
pmcid: 2536750
Zhang, T., Wei, H., Deng, J., Zheng, F. & Zhan, C.-G. Clinical potential of a rationally engineered enzyme for treatment of cocaine dependence: Long-lasting blocking of the psychostimulant, discriminative stimulus, and reinforcing effects of cocaine. Neuropharmacology 176, 108251. https://doi.org/10.1016/j.neuropharm.2020.108251 (2020).
doi: 10.1016/j.neuropharm.2020.108251
pubmed: 32710979
pmcid: 7530019
Chen, X. et al. Long-acting cocaine hydrolase for addiction therapy. Proc. Natl. Acad. Sci. 113(2), 422–427. https://doi.org/10.1073/pnas.1517713113 (2016).
doi: 10.1073/pnas.1517713113
pubmed: 26712009
Zheng, F. et al. Structure-based design and discovery of a long-acting cocaine hydrolase mutant with improved binding affinity to neonatal Fc receptor for treatment of cocaine abuse. AAPS J. 22(3), 62. https://doi.org/10.1208/s12248-020-00442-3 (2020).
doi: 10.1208/s12248-020-00442-3
pubmed: 32189158
Zheng, F. et al. Development of a highly efficient long-acting cocaine hydrolase entity to accelerate cocaine metabolism. Bioconjug. Chem. 33, 1340–1349. https://doi.org/10.1021/acs.bioconjchem.2c00210 (2022).
doi: 10.1021/acs.bioconjchem.2c00210
pubmed: 35767675
Deng, J., Zheng, X., Shang, L., Zhan, C. G. & Zheng, F. Gender differences in cocaine-induced hyperactivity and dopamine transporter trafficking to the plasma membrane. Addict. Biol. 27(6), e13236. https://doi.org/10.1111/adb.13236 (2022).
doi: 10.1111/adb.13236
pubmed: 36301205
pmcid: 9625146
Deng, J., Zhang, T., Shang, L., Zhan, C.-G. & Zheng, F. Recovery of dopaminergic system after cocaine exposure and impact of a long-acting cocaine hydrolase. Addict. Biol. 27(4), e13179. https://doi.org/10.1111/adb.13179 (2022).
doi: 10.1111/adb.13179
pubmed: 35754103
pmcid: 9245253
Deng, J. et al. Cocaine hydrolase blocks cocaine-induced dopamine transporter trafficking to the plasma membrane. Addict. Biol. 27(1), e13089. https://doi.org/10.1111/adb.13089 (2022).
doi: 10.1111/adb.13089
pubmed: 34363291
Jasinski, D. R. & Henningfield, J. E. Human abuse liability assessment by measurement of subjective and physiological effects. NIDA Res. Monogr. 92, 73–100 (1989).
pubmed: 2512504
Colpaert, F. C., Niemegeers, C. J. E. & Janssen, P. A. J. Discriminative stimulus properties of cocaine: Neuropharmacological characteristics as derived from stimulus generalization experiments. Pharmacol. Biochem. Behav. 10(4), 535–546. https://doi.org/10.1016/0091-3057(79)90229-6 (1979).
doi: 10.1016/0091-3057(79)90229-6
pubmed: 37526
Schuster, C. & Johanson, C. Relationship between the discriminative stimulus properties and subjective effects of drugs. Transduct. Mech. Drug Stimuli 4, 161–175 (1988).
doi: 10.1007/978-3-642-73223-2_13
Holtzman, S. G. Discriminative stimulus effects of drugs: Relationship to potential for abuse (1990).
Stolerman, I. P. Chapter 9—Drug discrimination. In Techniques in the Behavioral and Neural Sciences Vol. 10 (ed. van Haaren, F.) 217–243 (Elsevier, 1993).
Buccafusco, J. J. (ed.) Methods of Behavior Analysis in Neuroscience (CRC Press/Taylor & Francis, 2009). 2nd edition. Boca Raton (FL). https://pubmed.ncbi.nlm.nih.gov/21204335/ .
Solinas, M., Panlilio, L. V., Justinova, Z., Yasar, S. & Goldberg, S. R. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat. Protocols 1(3), 1194–1206. https://doi.org/10.1038/nprot.2006.167 (2006).
doi: 10.1038/nprot.2006.167
pubmed: 17406402
Glennon, R. A., Järbe, T. U., Frankenheim, J. Drug discrimination: Applications to drug abuse research; US Department of Health and Human Services, Public Health Service, Alcohol … (1991).
Holtzman, S. & Locke, K. Neural mechanisms of drug stimuli: Experimental approaches. Transduct. Mech. Drug Stimuli 4, 139–153 (1988).
doi: 10.1007/978-3-642-73223-2_11
Dykstra, L. A., Doty, P., Johnson, A. B. & Picker, M. J. Discriminative stimulus properties of cocaine, alone and in combination with buprenorphine, morphine and naltrexone. Drug Alcohol Depend. 30(3), 227–234 (1992).
doi: 10.1016/0376-8716(92)90056-I
pubmed: 1396104
Colpaert, F. C. Drug discrimination in neurobiology. Pharmacol. Biochem. Behav. 64(2), 337–345. https://doi.org/10.1016/S0091-3057(99)00047-7 (1999).
doi: 10.1016/S0091-3057(99)00047-7
pubmed: 10515310
Overton, D. A. Applications and limitations of the drug discrimination method for the study of drug abuse. In Methods of Assessing the Reinforcing Properties of Abused Drugs (ed. Bozarth, M. A.) 291–340 (Springer, 1987).
doi: 10.1007/978-1-4612-4812-5_16
Collins, G. T. et al. Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. Neuropsychopharmacology 37(5), 1092–1103. https://doi.org/10.1038/npp.2011.226 (2012).
doi: 10.1038/npp.2011.226
pubmed: 21993206
Shang, L. et al. Catalytic activities of a highly efficient cocaine hydrolase for hydrolysis of biologically active cocaine metabolites norcocaine and benzoylecgonine. Sci. Rep. 13(1), 640. https://doi.org/10.1038/s41598-022-27280-x (2023).
doi: 10.1038/s41598-022-27280-x
pubmed: 36635293
pmcid: 9837138
Shang, L. et al. Effects of alcohol on metabolism and toxicity of cocaine in rats. Toxicol. Rep. 9, 1586–1594 (2022).
doi: 10.1016/j.toxrep.2022.08.001
pubmed: 36518391
pmcid: 9743458
Jufer, R. A., Walsh, S. L. & Cone, E. J. Cocaine and metabolite concentrations in plasma during repeated oral administration: Development of a human laboratory model of chronic cocaine use. J. Anal. Toxicol. 22, 435–444 (1998).
doi: 10.1093/jat/22.6.435
pubmed: 9788518
Fang, L. et al. Rational design, preparation, and characterization of a therapeutic enzyme mutant with improved stability and function for cocaine detoxification. ACS Chem. Biol. 9, 1764–1772 (2014).
doi: 10.1021/cb500257s
pubmed: 24919140
pmcid: 4136690
Gao, D. et al. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol. Pharmacol. 75(2), 318–323. https://doi.org/10.1124/mol.108.049486 (2009).
doi: 10.1124/mol.108.049486
pubmed: 18987161
Brim, R. L. et al. A thermally stable form of bacterial cocaine esterase: A potential therapeutic agent for treatment of cocaine abuse. Mol. Pharmacol. 77, 593–600 (2010).
doi: 10.1124/mol.109.060806
pubmed: 20086035
pmcid: 2845945
Collins, G. T. et al. Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J. Pharmacol. Exp. Ther. 331, 445–455 (2009).
doi: 10.1124/jpet.108.150029
pubmed: 19710369
pmcid: 2775252
Wei, H., Zhang, T., Zhan, C.-G. & Zheng, F. Cebranopadol reduces cocaine self-administration in male rats: Dose, treatment and safety consideration. Neuropharmacology 172, 108128. https://doi.org/10.1016/j.neuropharm.2020.108128 (2020).
doi: 10.1016/j.neuropharm.2020.108128
pubmed: 32389751
pmcid: 9334146
Wei, H., Shang, L., Zhan, C.-G. & Zheng, F. Effects of cebranopadol on cocaine-induced hyperactivity and cocaine pharmacokinetics in rats. Sci. Rep. 10(1), 9254. https://doi.org/10.1038/s41598-020-66250-z (2020).
doi: 10.1038/s41598-020-66250-z
pubmed: 32518276
pmcid: 7283222
Chen, X. et al. A quantitative LC-MS/MS method for simultaneous determination of cocaine and its metabolites in whole blood. J. Pharm. Biomed. Anal. 134, 243–251. https://doi.org/10.1016/j.jpba.2016.11.024 (2017).
doi: 10.1016/j.jpba.2016.11.024
pubmed: 27923200